Variables | Ventilator-dependent >100 days or non-survivors | Weaned from the ventilator | Univariate Analysis OR (95% CI) | Multivariate Analysis (Mode With SOFA) OR (95% CI) | Multivariate Analysis (Mode With SAPS II) OR (95% CI) |
---|---|---|---|---|---|
Subjects | 67 | 16 | |||
Age yrs | 68.0 (16) | 71.5 (21) | 1.01 (0.96-1.05) | 1.01 (0.95-1.07) | 1.03 (0.97-1.10) |
Gender | |||||
Female | 27 (40) | 9 (56) | 1.91 (0.63-5.73) | 1.62 (0.34-7.85) | 1.22 (0.27-5.59) |
Male | 40 (60) | 7 (44) | |||
Smoking | 29 (43) | 5 (31) | 0.60 (0.19-1.90) | 1.27 (0.23-7.05) | 0.83 (0.16-4.32) |
Co-morbidities | |||||
No | 34 (51) | 9 (56) | 0.80 (0.27-2.40) | - | - |
Yes | 33 (49) | 7 (43) | |||
ECOG-PS | |||||
0-2 | 20 (30) | 6 (38) | 0.71 (0.23-2.22) | - | - |
3-4 | 47 (70) | 10 (63) | |||
Type of lung cancer | |||||
Adenocarcinoma | 60 (90) | 16 (100) | - + | - | - |
Large cell | 7 (10) | 0 | |||
Cancer status | |||||
Controlled | 9 (13) | 2 (13) | 1.29 (0.23-7.19) | - | - |
Uncontrolled, newly diagnosed | 30 (45) | 6 (38) | |||
Uncontrolled, progression | 28 (42) | 8 (50) | |||
Treatment before respiratory failure | |||||
Combined therapy | 21 (31) | 3 (19) | 2.04 (0.47-8.91) | 2.18 (0.45-10.53) | 1.70 (0.36-7.99) |
EGFR TKI only | 6 (9) | 3 (19) | |||
Chemotherapy only | 24 (36) | 7 (44) | |||
No treatment | 16 (24) | 3 (19) | |||
Indication for MV | |||||
Pulmonary | 48 (72) | 10 (63) | 0.80 (0.09-7.40) | - | - |
Sepsis | 9 (13) | 2 (13) | |||
Cardiac | 6 (9) | 1 (6) | |||
Neurologic | 4 (6) | 3 (19) | |||
APACHE II score, points | 25.0 (12) | 21.0 (7) | 0.91 (0.82-1.00) | - | - |
SAPS II score, points | 55.0 (23) | 46.5 (15) | 0.94 (0.89-0.99)* | - | 0.92 (0.86-0.99)* |
SOFA score, points | 8.0 (4) | 6.0 (4) | 0.80 (0.65-0.98)* | 0.66 (0.46-0.94)* | - |
Use of vasopressors | 33 (49) | 6 (38) | 0.62 (0.20-1.89) | 3.77 (0.57-25.07) | 1.35 (0.33-5.50) |
Positive blood culture | 13 (19) | 2 (13) | 0.59 (0.12-2.94) | - | - |
Taking EGFR TKI | 18 (27) | 5 (31) | 1.24 (0.38-4.06) | 0.98 (0.26-3.77) | 1.14 (0.30-4.27) |